Woman scientist working at lab bench

Intellectual Property
At Our Core Resides A Powerful,
High-Throughput Discovery Engine

Intellectual Property

Ractigen possesses a prominent IP position in RNAa and oligonucleotide delivery. At Ractigen’s core resides a powerful, high-throughput discovery engine allowing for the rapid identification of saRNAs. Our portfolio is built on composition of matter and methods of use for a growing library of therapeutic oligonucleotides. Medicinal chemistries and delivery platforms developed exclusively in-house further strength our IP estate and empower drug development.


Our Discovery Engine

It features a highly-refined bioinformatics algorithm integrating epigenetic datasets, design rules, and genome-wide on-target prediction tethered to in-house oligonucleotide manufacturing for saRNA synthesis followed by automated experimental validation of saRNA activity.

Labeled arrows: Genetic Sequence, Target Identification, saRNA Synthesis, and HTS
Target Gene Locus icon

Target Gene Locus

Rapidly identify all saRNAs for any single target gene

Search Algorithm icon

Search Algorithm

bioinformatics algorithm

In-House Synthesis icon

In-House Synthesis

Oligonucleotide manufacturing for in-house saRNA synthesis

In vitro Screening & Gene Expression icon

In vitro Screening & Gene Expression

Automated rounds of dose-dependent gene expression

3-4 Weeks Start to Finish (All In-House)

Start to finish underline

Screen Hundreds of saRNA Candidates

Automated rounds of dose-dependent gene expression analytics and integrated de-risking safety assays allow for the screening of hundreds of saRNA candidates within 30-45 days.

Honing the Process

We are continually honing the process in pursuit of full-automation and continue to add to our ever-growing list of therapeutic genes expanding our IP estate and feeding our drug development pipeline.

Want to Discover More?

Check out our News. Below are some highlights to get you started.


June 10, 2023 in News Highlight

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically validate Ractigen’s proprietary CNS delivery platform enabling new oligonucleotides therapeutics in the CNS JIANGSU, CHINA…
Read More
March 3, 2023 in News Highlight

Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RAG-17, a novel siRNA modality for the treatment of…
Read More
January 27, 2022 in Company News

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital,…
Read More
February 10, 2021 in Company News

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed a 17$ million USD (¥110 million) Series A financing round led by Hillhouse Venture Capital…
Read More